Law360, New York (November 18, 2008, 12:00 AM ET) -- In a significant decision, the Supreme Court of Canada (Apotex Inc. v. Sanofi-Synthelabo Canada et al (2008 SCC 61)) upheld pharmaceutical selection patents but defined potentially more stringent tests for anticipation and obviousness.
The decision has given pharmaceutical companies reason to breath a cautious sigh of relief, although there was actually little doubt that selection patents as a concept would be upheld.
However, the Court also signaled a shift in Canada's approach to obviousness which brings Canada into closer alignment with the more flexible (and usually...
Plavix: A Significant Decision For Patent Holders
To view the full article, take a free trial now.
